Is TP53 dysfunction required for BRCA1-associated carcinogenesis?

Molecular and Cellular Endocrinology

Volumn 155, Issue 1-2, 1999, Pages 143-152

  Schuyer, Monique ^a   Berns, Els M J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BRCA1; DNA repair; Hereditary breast cancer; Hereditary ovarian cancer; TP53

Indexed keywords

ARTICLE; BREAST CARCINOGENESIS; CELL CYCLE; DNA DAMAGE; DNA REPAIR; GENE FUNCTION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL;

BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, P53; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032880757     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(99)00117-3     Document Type: Article

References (102)

1. An H.X., Beckmann M.F., Reifenberger G., Bender H.G., Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am. J. Pathol. 154:1999;113-118.
2. Anderson S.F., Schlegel B.P., Nakajima T., Wolpin E.S., Parvin J.D. BRCA1 protein is linked to RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19:1998;254-256.
3. Ansquer Y., Gautier C., Fourquet A., Asselain B., Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Lancet. 352:1998;541.
4. Berchuck A., Heron K.A., Carney M.E. et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin. Cancer Res. 4:1998;2433-2437.
5. Bork P., Hofmann K., Bucher P., Neuwald A.F., Altschul S.F., Koonin E.V. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB. 11:1997;68-76.
6. Brugarolas J., Jacks T. Double indemnity: p53, BRCA and cancer. Nat. Med. 3:1997;721-722.
7. Buchhop S., Gibson M.K., Wang X.W., Wagner P., Sturzbecher H.W., Harris C.C. Interaction of p53 with the human Rad51 protein. Nucleic Acids Res. 25:1997;3868-3874.
8. Chai Y.L., Cui J., Shao N., Reddy E.S.P., Rao V.N. The second BRCT domain of BRCA1 proteins interact with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene. 18:1999;263-268.
9. Chapman M.S., Verma I.M. Transcriptional activation by BRCA1. Nature. 382:1996;678-679.
10. Chen Y., Farmer A.A., Chen C.-F., Jones D.C., Chen P.-L., Lee W.-H. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle dependent manner. Cancer Res. 56:1996;3168-3172.
11. Chen J., Silver D.P., Walpita D. et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell. 2:1998;317-328.
12. Cornelis R.S., Neuhausen S.L., Johansson O. et al. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCA1-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer. 13:1995;203-210.
13. Crook T., Crossland S., Crompton M.R., Osin P., Gusterson B.A. p53 mutations in BRCA1-associated familial breast cancer. Lancet. 350:1997;638-639.
14. Crook T., Brooks L.A., Crossland S. et al. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene. 17:1998;1681-1689.
15. Cropp C.S., Champeme M.H., Lidereau R., Callahan R. Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. Cancer Res. 53:1993;5617-5619.
16. Cui J.Q., Shao N., Chai Y., Wang H., Reddy E.S., Rao V.N. BRCA1 splice variants BRCA1a and BRCA1b associate with CBP co-activator. Oncol. Rep. 5:1998;591-595.
17. Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57:1997;3347-3350.
18. Dudenhoffer C., Rohaly G., Will K., Deppert W., Wiesmuller L. Specific mismatch recognition in heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination. Mol. Cell. Biol. 18:1998;5332-5342.
19. Easton D.F., Ford D., Bishop D.T Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56:1995;265-271.
20. Eisinger F., Stoppa-Lyonnet D., Longy M. et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 56:1996;471-474.
21. Fan S., Wang J.-A., Yuan R. et al. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene. 16:1998;3069-3082.
22. Ford D., Easton D.F., Bishop D.T., Narod S.A., Goldgar D.E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 343:1994;692-695.
23. Foulkes W.D., Black D.M., Stamp G.W., Solomon E., Trowsdale J. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int. J. Cancer. 54:1993;220-225.
24. Foulkes W.D., Wong N., Brunet J.S. et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin. Cancer Res. 3:1997;2465-2469.
25. Futreal P.A., Liu Q., Shattuck-Eidens D. et al. BRCA1 mutation in primary breast and ovarian carcinomas. Science. 266:1994;120-122.
26. Gayther S.A., Warren W., Mazoyer S. et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat. Genet. 11:1995;428-433.
27. Glebov O.K., McKenzie K.E., White C.A., Sukumar S. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res. 54:1994;3703-3709.
28. Gowen L.C., Johnson B.L., Latour A.M., Sulik K.K., Koller B.H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12:1996;191-194.
29. Gowen L.C., Avrutskaya A.V., Latour A.M., Koller B.H., Leadon S.A. BRCA1 is required for transcription-coupled repair of oxidative DNA damage. Science. 281:1998;1009-1012.
30. Gudas J.M., Nguyen H., Li T., Cowan K.H. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res. 55:1995;4561-4565.
31. Gudas J.M., Li T., Nguyen H., Jensen D., Rauscher III F.J., Cowan K.H. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ. 7:1996;717-723.
32. Hakem R., de la Pompa J.L., Sirard C. et al. The tumour suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell. 85:1996;1009-1023.
33. 5-6 early embryonic lethality by p53 or p21 null mutation. Nat. Genet. 16:1997;298-302.
34. Holt J.T., Thompson M.E., Szabo C. et al. Growth retardation and tumour inhibition by BRCA1. Nat. Genet. 12:1996;298-302.
35. Hosking L., Trowsdale J., Nicolai H. et al. A somatic BRCA1 mutation in an ovarian tumour. Nat. Genet. 9:1995;343-344.
36. Hussain S.P., Harris C.C. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 58:1998;4023-4037.
37. Jacquemier J., Eisinger F., Birnbaum D., Sobol H. Histoprognostic grade in BRCA1-associated breast cancer. Lancet. 345:1995;1503.
38. Jensen R.A., Thompson M.E., Jetton T.L. et al. BRCA1 is secreted and exhibits properties of a granin. Nat. Genet. 12:1996;303-308.
39. Jensen D.E., Proctor M., Marquis S.T. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 16:1998;1097-1112.
40. Jin Y., Xu X.L., Yang M.C. et al. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc. Natl. Acad. Sci. USA. 94:1997;12075-12080.
41. Johannsson O.T., Idvall I., Anderson C. et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer. 33:1997;362-371.
42. Johannsson O.T., Ranstam J., Borg A., Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J. Clin. Oncol. 16:1998;397-404.
43. Kinzler K.W., Vogelstein B. Gatekeepers and caretakers. Nature. 386:1997;761-762.
44. Koonin E.V., Altschul S.F., Bork P. BRCA1 protein products...functional motifs... Nat. Genet. 13:1996;266-268.
45. Li S., Chen P.L., Subramanian T. et al. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J. Biol. Chem. 274:1999;11334-11338.
46. Lim D.S., Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol. Cell. Biol. 16:1996;7133-7143.
47. Liu C.Y., Flesken-Nikitin A., Li S., Zeng Y., Lee W.H. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10:1996;1835-1843.
48. Ludwig T., Chapman D.L., Papaioannou V.E., Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11:1997;1226-1241.
49. Marcus J.N., Watson P., Page D.L. et al. Hereditary breast cancer: pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer. 77:1996;697-709.
50. Marks J.R., Huper G., Vaughn J.P. et al. BRCA1 expression is not directly responsive to estrogen. Oncogene. 14:1997;115-121.
51. Marquis S.T., Rajan R.V., Wynshaw-Boris A. et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat. Genet. 11:1995;17-26.
52. Mekeel K.L., Tang W., Kachnic L.A., Luo C.M., DeFrank J.S., Powell S.N. Inactivation of p53 results in high rates of homologous recombination. Oncogene. 14:1997;1847-1857.
53. Merajver S.D., Frank T.S., Xu J. et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin. Cancer Res. 1:1995;539-544.
54. Merajver S., Pham T.M., Caduff R.F. et al. Somatic mutations in sporadic ovarian tumours. Nat. Genet. 9:1995;439-443.
55. Monteiro A.N.A., August A., Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc. Natl. Acad. Sci. USA. 93:1996;13595-13599.
56. Miki Y., Swensen J., Shattuck-Eidens D. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
57. Nagai M.A., Yamamoto L., Salaorni S. et al. Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumours. Genes Chromosomes Cancer. 11:1994;58-62.
58. Neuhausen S.L., Marshall C.J. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 54:1994;6069-6072.
59. Özçelik H., To M.D., Couture J., Bull S.B., Andrulis I.L. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int. J. Cancer. 77:1998;1-6.
60. Ouchi T., Monteiro A.N.A., August A., Aaronson S.A., Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. USA. 95:1998;2302-2306.
61. Phillips K.A., Nichol K., Ozcelik H. et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J. Natl. Cancer Inst. 91:1999;469-473.
62. Rhei E., Bogomolniy F., Federici M.G. et al. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res. 58:1998;3193-3196.
63. Rice J.C., Massey-Brown K.S., Futscher B.W. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene. 17:1998;1807-1812.
64. Robson M., Gilewski T., Haas B. et al. BRCA-associated breast cancer in young women. J. Clin. Oncol. 16:1998;1642-1649.
65. Rubin S.C., Benjamin I., Behbakht K. et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. New Engl. J. Med. 335:1996;1413-1416.
66. Saito H., Inazawa J., Saito S. et al. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res. 53:1993;3382-3385.
67. Saretzki G., Hoffmann U., Rohlke P. et al. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer. 80:1997;1241-1249.
68. Saurin A.J., Borden K.L., Boddy M.N., Freemont P.S. Does this have a familiar RING? Trends Biochem. Sci. 21:1996;208-214.
69. Schildkraut J.M., Collins N.K., Dent G.A. et al. Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer. Am. J. Obstet. Gynecol. 172:1995;908-913.
70. Schlichtholz B., Bouchind'homme B., Pagés S. et al. p53 Mutations in BRCA1-associated familial breast cancer. Lancet. 352:1998;622.
71. Arg→Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of the Netherlands. Int. J. Cancer. 76:1998;299-303.
72. Scully R., Ganesan S., Brown M. et al. Location of BRCA1 in human breast and ovarian cancer cell lines. Science. 272:1996;123-125.
73. Scully R., Chen J., Ochs R.L. et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell. 90:1997;425-435.
74. Scully R., Anderson S.F., Chao D.M. et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc. Natl. Acad. Sci. USA. 94:1997;5605-5610.
75. Scully R., Chen J., Plug A. et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 88:1997;265-275.
76. Sharan S.K., Morimatsu M., Albrecht U. et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 386:1997;804-810.
77. Shattuck-Eidens D., McClure M., Simard J. et al. A collobarative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibilty gene. Implications for presymptomatic testing and screening. J. Am. Med. Assoc. 273:1995;535-541.
78. Shinohara A., Ogawa H., Ogawa T. Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell. 69:1992;457-470.
79. Shiohara M., el-Deiry W.S., Wada M. et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
80. Smith S.A., Easton D.F., Evans D.G., Ponder B.A. Allele loss in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat. Genet. 2:1992;128-131.
81. Sobol H., Stoppa-Lyonnet D., Bressac-de-Paillerets B. et al. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res. 56:1996;3216-3219.
82. Sobol H., Stoppa-Lyonnet D., Bressac-de Paillerets B. et al. BRCA1-p53 relationship in hereditary breast cancer. Int. J. Oncol. 10:1997;349-353.
83. WAF1/CIP1. Nature. 389:1997;187-190.
84. Struewing J.P., Hartge P., Wacholder S. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl. J. Med. 336:1997;1401-1408.
85. Sturzbecher H.W., Donzelmann B., Henning W., Knippschild U., Buchhop S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 15:1996;1992-2002.
86. Takahashi H., Behbakht K., McGovern P.E. et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 55:1995;2998-3002.
87. Tanner M.M., Karhu R.A., Nupponen N.N. et al. Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am. J. Pathol. 153:1998;191-199.
88. Thai T.H., Du F., Tsan J.T. et al. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum. Mol. Genet. 7:1998;195-202.
89. Thakur S., Zhang H.B., Peng Y. et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol. Cell. Biol. 17:1997;444-452.
90. Thompson M.E., Jensen R.A., Obermiller P.S., Page D.L., Holt J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet. 9:1995;444-450.
91. Thor A.D., Moore II D.H., Edgerton S.M. et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst. 84:1992;845-855.
92. Tirkkonen M., Johannsson O., Agnarsson B.A. et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57:1997;1222-1227.
93. Vaughn J.P., Davis P.L., Jarboe M.D. et al. BRCA1 expression is induced before DNA synthesis in both normal and tumor derived breast cells. Cell Growth Differ. 7:1996;711-715.
94. Verhoog L.C., Brekelmans C.T.M., Seynave C. et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 351:1998;316-321.
95. Wagner T.M.U, Möslinger R.A., Muhr D. et al. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int. J. Cancer. 77:1998;354-360.
96. Wang H., Shao N., Ding Q.M., Cui J., Reddy E.S.P., Rao V.N. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins, and cyclin dependent kinases. Oncogene. 15:1997;143-157.
97. Wang Q., Zhang H., Kajino K., Greene M.I. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene. 17:1998;1939-1948.
98. Wilson C.A., Payton M.N., Elliot G.S. et al. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene. 14:1997;1-16.
99. Wong A.K.C., Pero R., Ormonde P.A., Tavtigian S.V., Bartel P.L. RAD51 interacts with the evolutionary conserved BRC motifs in the human breast cancer susceptibility gene brca2. J. Biol. Chem. 272:1997;31941-31944.
100. Wong A.K.C., Ormonde P.A., Pero R. et al. Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene. 17:1998;2279-2285.
101. Wu L.C., Wang Z.W., Tsan J.T. et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 14:1996;430-440.
102. Zhang H., Somasundaram K., Peng Y. et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 16:1998;1713-1721.